Stereospecific ligands and their complexes. Part XII. Synthesis, characterization and in vitro antiproliferative activity of platinum(IV) complexes with some O,O′-dialkyl esters of (S,S)-ethylenediamine-N,N′-di-2-propanoic acid against colon cancer (HCT-116) and breast cancer (MDA-MB-231) cell lines

Stojković, Danijela Lj.; Jevtić, Verica V.; Đačić, Dragana S.; Ćurčić, Milena; Marković, Snežana D.; Đinović, Vesna M.; Petrović, Zorica D.; Trifunović, Srećko R.

doi:10.1016/j.molstruc.2014.01.020

Cited by 13 publications

(10 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We also observed better cytotoxic effect of Pt‐L2‐Zn complex on MDA‐MB‐231 cells after 72 hr in our study, when compared to mononuclear [ZnCl 2 (en)] complex. Effects of Pt‐L1‐Zn and Pt‐L2‐Zn complexes can be also compared with effects of Pt(IV) complexes (containing alkyl esters of some edda‐type ligands) that have been already tested on these cell lines [ 28 ] and it can be concluded that Pt‐L‐Zn complexes showed better and stronger activity against HCT‐116 and MDA‐MB‐231 cells in our study.…”

Section: Resultsmentioning

confidence: 68%

Novel heteronuclear Pt (II)‐L‐Zn (II) complexes: synthesis, interactions with biomolecules, cytotoxic properties. Two metals give promising antitumor activity?

Soldatović

Selimović

Milivojević

et al. 2020

Applied Organom Chemis

View full text Add to dashboard Cite

The novel heteronuclear complexes [{cis‐PtCl (NH3)(μ‐pyrazine)ZnCl (terpy)}](ClO4)2 (Pt‐L1‐Zn) and [{cis‐PtCl (NH3)(μ‐4,4′‐bipyridyl)ZnCl (terpy)}](ClO4)2 (Pt‐L2‐Zn) (where terpy = 2,2′:6′,2′′‐terpyridine, L1 = pyrazine, L2 = 4,4′‐bipyridyl) were synthesized and characterized. The pKa values were determined, and based on them it was established that the π‐acceptor ability of the pyrazine bridging ligand is more affective on lower pKa values. The kinetic measurements of the substitution reactions with biologically relevant ligands, such as guanosine‐5′‐monophosphate (5′‐GMP), inosine‐5′‐monophosphate (5′‐IMP) and glutathione (GSH), were studied at pH 7.4. The reactions were followed under pseudo‐first‐order conditions by UV–Vis spectrophotometry. The order of reactivity of the investigated biomolecules for the first reaction is 5′‐GMP > 5′‐IMP > GSH, while for the second is 5′‐IMP > GSH. Pt‐L1‐Zn complex is more reactive than Pt‐L2‐Zn. The cytotoxic activity of heteronuclear Pt‐L1‐Zn and Pt‐L2‐Zn complexes was determined on human colorectal cancer cell line (HCT‐116) and human breast cancer cell line (MDA‐MB‐231). Both complexes significantly reduced cell viability on tested cell lines and exerted significant cytotoxic effects, with better effect on HCT‐116 cells than cisplatin, especially after 72 hr (IC50 < 0.52 μM). The Pt‐L2‐Zn complex showed higher activity against human breast cancer cells (MDA‐MB‐231) than cisplatin after 72 hr. The higher reactivity toward DNA constituent and significant cytotoxic activity may be attributed to the different geometry, Lewis acidity of different metal centers, as well as, to choice of bridging ligands.

show abstract

Section: Resultsmentioning

confidence: 68%

Novel heteronuclear Pt (II)‐L‐Zn (II) complexes: synthesis, interactions with biomolecules, cytotoxic properties. Two metals give promising antitumor activity?

Soldatović

Selimović

Milivojević

et al. 2020

Applied Organom Chemis

View full text Add to dashboard Cite

show abstract

“…The results of cytotoxicity against MRC-5 (non-tumorigenic cells) for complex 10 were much higher than for cisplatin. All examined complexes showed significant cytotoxicity compared with cisplatin (Petrović et al, 2015) or with some other platinum(IV) complexes (Stojković et al, 2014) and palladium(II) complexes (Altaf et al, 2017).…”

Section: Cytotoxic Activity Of Gold(iii) Complexesmentioning

confidence: 95%

Gold(III) Complexes: An Overview on Their Kinetics, Interactions With DNA/BSA, Cytotoxic Activity, and Computational Calculations

Radisavljević

Petrović

2020

Front. Chem.

View full text Add to dashboard Cite

In the last few years, metallodrugs play a key role in the development of medicinal chemistry. The choice of metal ion, its oxidation state and stability, and the choice of inert and labile ligands are just some of the very important facts which must be considered before starting the synthesis of complexes with utilization in medicinal purpose. As a result, a lot of compounds of different transition metal ions found application for diagnostic and therapeutic purpose. Beside all, gold compounds have attracted particular attention. It is well-known that gold compounds could be used for the treatment of cancer, HIV, rheumatoid arthritis (chrysotherapy), and other diseases. This metal ion has unoccupied d-sublevels and possibility to form compounds with different oxidation states, from −1 to +5. However, gold(I) and gold(III) complexes are dominant in chemistry and medicine. Especially, gold(III) complexes are of great interest due to their structural similarity with cisplatin. Accordingly, this review summarizes the chemistry of some mononuclear and polynuclear gold(III) complexes. Special attention is given to gold(III) complexes with nitrogen-donor inert ligands (aliphatic or aromatic that have a possibility to stabilize complex) and their kinetic behavior toward different biologically relevant nucleophiles, mechanism of interaction with DNA/bovine serum albumin (BSA), cytotoxic activity, as well as computational calculations.

show abstract

“…In addition, it was reported that three novel platinum(IV) complexes were synthesized and screened for their anticancer activity. Compound 151 (Figure 21) showed the highest cytotoxic activity against MDA-MB-231 (IC 50 = 68.023 µM) with induction of apoptosis [128].…”

Section: Miscellaneous Anti-breast Cancer Agentsmentioning

confidence: 99%

Recent Advancements in the Development of Anti-Breast Cancer Synthetic Small Molecules

Elkaeed

Salam²,

Sabt³

et al. 2021

Molecules

View full text Add to dashboard Cite

Among all cancer types, breast cancer (BC) still stands as one of the most serious diseases responsible for a large number of cancer-associated deaths among women worldwide, and diagnosed cases are increasing year by year worldwide. For a very long time, hormonal therapy, surgery, chemotherapy, and radiotherapy were used for breast cancer treatment. However, these treatment approaches are becoming progressively futile because of multidrug resistance and serious side effects. Consequently, there is a pressing demand to develop more efficient and safer agents that can fight breast cancer belligerence and inhibit cancer cell proliferation, invasion and metastasis. Currently, there is an avalanche of newly designed and synthesized molecular entities targeting multiple types of breast cancer. This review highlights several important synthesized compounds with promising anti-BC activity that are categorized according to their chemical structures.

show abstract

Cited by 13 publications

References 35 publications

Novel heteronuclear Pt (II)‐L‐Zn (II) complexes: synthesis, interactions with biomolecules, cytotoxic properties. Two metals give promising antitumor activity?

Novel heteronuclear Pt (II)‐L‐Zn (II) complexes: synthesis, interactions with biomolecules, cytotoxic properties. Two metals give promising antitumor activity?

Gold(III) Complexes: An Overview on Their Kinetics, Interactions With DNA/BSA, Cytotoxic Activity, and Computational Calculations

Recent Advancements in the Development of Anti-Breast Cancer Synthetic Small Molecules

Contact Info

Product

Resources

About